⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

JNJ News

Johnson & Johnson

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer